Skip to content

D&A at other companies

Baxter International logo
Baxter InternationalBAX
$237M-4.0%
LeMaitre Vascular logo
LeMaitre VascularLMAT
$2.62M+2.8%
Medtronic logo
MedtronicMDT
$716M-14.8%

Other financials

Income statement

See full
Revenue$61.5M+26.6%
Gross profit$46.2M+32.2%
Operating income-$2.8M-70.5%
Net income-$19.6M-411%
EPS (diluted)-$0.38-375%

Balance sheet

See full
Cash & equivalents$84.7M+251%
Total debt$20.6M-69.8%
Total equity$244.8M+132%
Total assets$289.5M+47.6%

Cash flow

See full
Operating cash flow$1.6M+112%
CapEx$2.8M+989%
Free cash flow-$1.2M+90.9%

Valuation

See full
Market cap$2.26B+110%

Profitability

See full
Gross margin75%+0.8pp
Operating margin-3.8%
Net margin-13.2%-22.8pp
FCF margin-12.9%-3.8pp

Returns & leverage

See full
Return on equity-18%-70.5pp
Debt / equity0.1×-0.6×
Current ratio7.1×+2.8×

Where this comes from

Reported directly by Axogen in its filing.

Tagged under the XBRL concept us-gaap:DepreciationDepletionAndAmortization.

The official record: Axogen’s 10-Q, filed April 28, 2026, on SEC EDGAR. View the filing →

Ask your AI about Axogen's d&a.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is Axogen's D&A?
Axogen (AXGN) reported D&A of $1.6M in Q1 2026.
How has Axogen's D&A changed year-over-year?
Axogen's D&A decreased by 7.2% year-over-year, from $1.73M to $1.6M.
What is the long-term trend for Axogen's D&A?
Over 4 years (2021 to 2025), Axogen's D&A has grown at a 24.8% compound annual growth rate (CAGR), from $2.74M to $6.66M.
What does D&A mean?
Total non-cash depreciation of tangible assets and amortization of intangible assets — the largest add-back to net income in the operating cash flow reconciliation.